ABSTRACT
-Current chemotherapy approaches to patients with malignant gliomas have little impact
on patient outcomes. Surgical and radiotherapy, although providing the majority of
benefit, have little potential for significant further improvement of patient survival.
Medical therapy, especially with expanding knowledge relative to tumor resistance,
oncogenesis pathways, and angiogenesis, has great potential for altering the outcomes
of patients with malignant gliomas. New cytotoxic agents such as temozolomide and
CPT-11 appear to have significant activity; however, anti-angiogenesis therapy, gene
therapies directed at oncogenic pathways, and immuno-toxin constructs may have the
greatest potential. Only by participation in clinical trials can these new agents
be developed to benefit future patients with malignant gliomas.
KEYWORD
Chemotherapy - malignant gliomas - drug therapy development
